Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Tolerability of 9vHPV Vaccine in Young Men and Women
NCT01651949Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2012
- Primary completion
- Aug 2014
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in genital warts, anal cancer, anal intraepithelial neoplasia (AIN), sponsored by Merck & Co.. Started Oct 2012; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
genital wartsanal canceranal intraepithelial neoplasia (AIN)
Beyond the preview
Go deeper on NCT01651949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01651949.